5.86
-1.18%
Close of 9 Nov 2026, in BRL
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biomm
Its shares trade on B3 under the ticker BIOM3.SA. It has been listed since 5 September 2002. In the fiscal year to 31 December 2025, it reported revenue of BRL 269.3m and a net loss of BRL 6.7m. At that date it held total assets of BRL 524.2m and shareholders' equity of BRL 313.5m.
BIOMM SA engages in the research, development, and manufacture of insulin. The company is headquartered in Nova Lima, Minas Gerais. The company went IPO on 2002-09-05. The firm is principally engaged in the development and licensing of technology for the production of human insulin and other recombinant proteins. The Company’s technology is suitable for the production of therapeutic proteins, which are used in the production of drugs and biopharmaceuticals. The Company’s technology for insulin production is protected by patents in various countries in Europe, Asia, North and South America. In addition, it is active in the development of production process of enzymes that are used in the hydrolysis of biomass and in the manufacture of bio-fuel. As of December 31, 2011, the Company’s subsidiaries were Biomm International Inc, Biomm Middle East Inc and Biomm Russia Ltd.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 5 Sept 2002
- Website
- biomm.com ↗
Leadership
Pay as last reported
- Guilherme Caldas EmrichChairman of the Board
- Mr. Francisco Carlos Marques de FreitasChief Executive Officer, Member of the Executive Board, since 2015
- Luciano VillelaMember of the Executive Board
- Italo Aurelio GaetaniDirector
- Roberto Antonio Pinto de Melo CarvalhoDirector
- Walfrido Silvino dos Mares GuiaIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biomm SA holds patents for insulin production technology in Europe, Asia, North and South America.
- Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd are key subsidiaries supporting global operations.
- Biomm SA develops recombinant proteins for therapeutic drugs and biopharmaceuticals.
Weaknesses
- Biomm SA's insulin technology is limited to production of human insulin and recombinant proteins.
- Biomm SA has no subsidiaries in Africa or Oceania regions.
- Biomm SA's business focuses on insulin and enzyme production without diversification into other biotech areas.
Opportunities
- Biomm SA can expand enzyme production for bio-fuel applications in biomass hydrolysis.
- Biomm SA can leverage its insulin patents to enter new markets in Asia and South America.
- Biomm SA can develop new recombinant proteins for additional therapeutic drugs.
Threats
- Biomm SA faces competition from established insulin manufacturers in Europe and North America.
- Biomm SA's enzyme production for bio-fuel may face regulatory challenges in biomass hydrolysis.
- Biomm SA's reliance on insulin technology could be threatened by new biotech innovations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.